Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Approaches to Inflammatory Myopathy

Vanessa Caceres  |  Issue: February 2011  |  February 12, 2011

Dr. Lundberg also reported on the results of several other studies that tracked the results of exercise in patients with myositis. The studies that she presented found, among other factors, a significant improvement in strength, maximum oxygen uptake, and activities of daily living. Another conclusion from these studies is that the use of creatine helped improve muscle performance.6,7

More studies are needed to track the benefits of exercise in patients with sporadic inclusion body myositis and juvenile dermatomyositis, she noted.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Lundberg said that as soon as patients on immunosuppressive therapy at her clinic feel they can do exercise, physicians will instruct them to follow a regimen with a physical therapist’s supervision.

“We can say that exercise is safe, at least in polymyositis and dermatomyositis, and that it seems to be effective to improve strength and fitness. I would suggest it as a complement to physical therapy. It may even be that exercise is beneficial to inflammation,” she said. “It may be provocative, but I’d like to suggest that exercise is medicine.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Vanessa Caceres is a freelance medical writer in Bradenton, Florida.

References

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.
  2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-407.
  3. Sokka T, Hetland ML, Mäkinen H, et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008; 58:2642-2651.
  4. Wiesinger GF, Quittan M, Nuhr M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil. 2000;81:1-5.
  5. Alexanderson H, Stenström CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: A pilot study. Rheumatology (Oxford). 1999;38:608-611.
  6. Wiesinger GF, Quittan M, Graninger M,et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol. 1998;37:1338-1342.
  7. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;57:694-702.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:2010 ACR/ARHP Annual Scientific MeetingDiagnostic Criteriainflammatory myopathyPathogenesisResearchrheumatologistTreatment

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Inflammatory Myopathies Difficult to Diagnose, Treat

    December 1, 2013

    Without a single set of diagnostic criteria for identifying polymyositis, dermatomyositis, or myositis and scant evidence-based therapeutic guidelines, these rare muscle diseases can be hard to manage

    Myositis Mysteries

    January 1, 2008

    Why isn’t my myositis patient getting better?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences